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Letter to the Editor
More gastro-intestinal adverse events in
non-ICU hospitalised COVID-19 patients treated
with chloroquine versus hydroxychloroquine
With great interest we read the observational cohort study of
Lammers and colleagues, in which they investigated the effect of
hydroxychloroquine and chloroquine in non-ICU hospitalized
COVID-19 patients. They found that early treatment with
hydroxychloroquine was associated with a reduced risk of transfer
to the ICU, whereas chloroquine did not reduce this risk. A possible
explanation for the observed difference of hydroxychloroquine as
compared to chloroquine might be a better safety profile of
hydroxychloroquine (Liu et al., 2020; Pereira, 2020; Yao et al.,
2020).
Known adverse events in hydroxychloroquine and chloroquine
are neurotoxicity, cardiotoxicity and gastro-intestinal symptoms.
We conducted an observational cohort study, comparing gastro-
intestinal adverse events in non-ICU hospitalized COVID-19 patients
treated with chloroquine versus hydroxychloroquine. The study
population consisted of all patients  18 years with proven COVID-19
of moderate severity, hospitalized in a non-ICU setting in Radbou-
dumc or Rijnstate Hospital and treated with hydroxychloroquine
(Rijnstate Hospital) or chloroquine (Radboud University Medical
Center) between March 3, 2020 and May 1, 2020. The primary
outcome was discontinuation of treatment course due to gastro-
intestinal adverse events (diarrhea, nausea, abdominal pain, newly
developed after start of treatment course). The analysis included
multivariable logistic regression corrected for age (the two cohorts
were relatively homogeneous except for the factor of age).
A total of 246 patients were included in the study, with 166
patients in the hydroxychloroquine group and 80 patients in the
chloroquine group. In the hydroxychloroquine group 1.3% of the
patients discontinued the treatment course due to gastro-
intestinal adverse events, compared to 17% in the chloroquine
group (p < 0.001; OR 17 [95% CI 3.4–80]). The incidence of gastro-
intestinal adverse events was significantly higher in the chloro-
quine group (40%) compared to the hydroxychloroquine group
(18%) (p < 0.001; OR 3.0 [95%CI 1.6–5.6]) (Table 1). These findings
suggest that treatment with chloroquine was associated with an
increased risk for gastro-intestinal adverse events, which subse-
quently led to an increased risk for discontinuing treatment,
compared to hydroxychloroquine.
This study shows that, over short term use, chloroquine causes
more gastro-intestinal adverse events than hydroxychloroquine at
dosages given for COVID-19. When considering the outcome of the
study of Lammers et al., the observed difference in risk for transfer
to the ICU between patients treated with hydroxychloroquine
versus chloroquine could be partially explained by the observed
difference in gastro-intestinal adverse events.
Table 1










Completeness of treatment course
(n = 149 and n = 79)
Completed treatment course 123/149 (83) 46/79 (58) <0.001*
Discontinued treatment course 26/149 (17) 33/79 (42) <0.001*
Due to gastro-intestinal adverse events 2/149 (1.3) 13/79 (17) <0.001* 17 (3.4–80)*
- Nausea/vomiting 2/149 (1.3) 8/79 (10) 0.009* 9.0 (1.7–47)*
- Diarrhea 0/149 (0.0) 5/79 (6.3) NAb NAb
- Abdominal pain 0/149 (0.0) 0/79 (0.0) NAb NAb
Gastro-intestinal adverse events 30/166 (18) 32/80 (40) <0.001* 3.0 (1.6–5.6)*
- Nausea/vomiting 18/166 (11) 18/80 (23) 0.013* 2.6 (1.2–5.4)*
- Diarrhea 13/166 (7.8) 20/80 (25) 0.001* 3.6 (1.7–7.8)*
- Abdominal pain 6/166 (3.6) 0/80 (0.0) NAb NAb
Requirement for comedication duringtreatment
Start of antiemetics during treatment 20/166 (12) 13/80 (16) 0.354 1.5 (0.7–3.2)
- Metoclopramide 19/166 (11) 12/80 (15)
- Other 3/166 (1.8) 1/80 (1.3)
Start of loperamide during treatment 1/166 (0.6) 5/80 (6.3) 0.029* 11 (1.3–103)*
* Statistically significant (p-value <0.05).
a Tested with multivariable logistic regression adjusted for age categories.
b Not available (NA), logistic regression test not possible due to zero frequencies.
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